News
-
-
PRESS RELEASE
Protagonist Therapeutics to Host Conference Call to Announce an Oral Peptide IL-17 Antagonist Development Candidate
Protagonist Therapeutics to host conference call and webcast on November 21st at 4:30 pm ET to announce oral peptide IL-17 antagonist development. Details: dial-in and webcast link provided -
-
PRESS RELEASE
Protagonist Announces Positive Topline Results From Phase 3 ICONIC Studies of Icotrokinra (JNJ-2113), a First-in-Class Investigational Targeted Oral Peptide That Selectively Blocks the IL-23 Receptor in Plaque Psoriasis
Protagonist announces positive Phase 3 ICONIC study results of icotrokinra, a first-in-class oral peptide for plaque psoriasis, achieving key endpoints and milestone payments under Johnson & Johnson collaboration -
-
PRESS RELEASE
Protagonist Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Protagonist Therapeutics reports financial results and upcoming milestones for Phase 3 clinical trials in psoriasis and ulcerative colitis, Phase 3 trials in polycythemia vera, and oral peptide antagonist development candidate nomination -
-
PRESS RELEASE
Protagonist Therapeutics Announces Poster Presentation on Final REVIVE Phase 2 Study Data with Rusfertide at the 66th Annual ASH Meeting
Protagonist Therapeutics to present final data from Phase 2 REVIVE study on rusfertide in polycythemia vera at ASH 66th Annual Meeting. Company focus on late-stage biopharmaceutical development -
-
PRESS RELEASE
Protagonist Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference 2024
Protagonist Therapeutics, Inc. to participate in H.C. Wainwright 26th Annual Global Investment Conference with CEO Dinesh V. Patel in fireside chat. Focus on Phase 3 clinical development of rusfertide and JNJ-2113
